Stemcell Holdings Inc (STMM)
0.06
0.00 (0.00%)
USD |
OTCM |
May 03, 16:00
Stemcell Holdings SG&A Expense (Quarterly): 0.8358M for Sept. 30, 2018
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
September 30, 2018 | 0.8358M |
June 30, 2018 | 1.197M |
March 31, 2018 | 0.47M |
December 31, 2017 | 0.409M |
September 30, 2017 | 0.351M |
June 30, 2017 | 0.2759M |
Date | Value |
---|---|
March 31, 2017 | 0.3585M |
December 31, 2016 | 0.1955M |
September 30, 2016 | 0.0711M |
June 30, 2016 | 0.051M |
March 31, 2016 | 0.0045M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
AIM ImmunoTech Inc | 10.86M |
Perspective Therapeutics Inc | 1.694M |
Protalix BioTherapeutics Inc | 4.143M |
Electromed Inc | 8.175M |
Armata Pharmaceuticals Inc | 3.179M |